ReviewJournal of translational medicine2025
Hierarchical therapeutic potential in the mesenchymal stem cell landscape.
Review in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mesenchymal stem cells (MSCs) are heterogeneous and versatile cells comprising distinct subpopulations with varying regenerative potential. MSCs have been widely explored in clinical research owing to their regenerative, tissue trophic, immune modulatory, and anti-inflammatory properties. Tissue-sourced autologous and allogeneic MSCs including those isolated from bone marrow, adipose tissue, and umbilical cord have been applied to clinical studies of a breadth of indications, providing ample evidence supporting the safety of MSC-based therapies. In some instances, clinical studies of MSCs have yielded variability in cell quality, potency, and therapeutic impact. Significantly, the Food and Drug Administration’s approval of the first MSC therapy, the allogeneic bone marrow MSC product Remestemcel-L-rknd (Ryoncil®), has fueled optimism for the clinical prospects of other investigational MSC products. The functional heterogeneity of MSCs has been demonstrated by studies of MSC subpopulations, often selected by surface marker expression or functional characteristics, that vary in clonogenicity, immunomodulatory potency, trophic factor production, and differentiation potential. While MSCs possess the ability to differentiate into mesodermal lineage cells, the potential for transdifferentiation of MSCs has been a matter of extensive scientific debate. There has been a strong impetus to identify MSC subpopulations that may possess enhanced self-renewal capabilities, higher clonogenicity, and greater plasticity. Certain MSC subpopulations, defined by specific surface markers or functional traits, have been reported to exhibit or enhanced therapeutic attributes compared to heterogeneous MSCs. Specific MSC subpopulations that have been examined include STRO-1 + cells, STRO-3-selected cells, CD146 + cells, CD271 + cells, aldehyde-dehydrogenase-expressing cells, side population (SP) cells, and stage-specific embryonic antigen-3 (SSEA-3) + cells. Due to the lack rigorous characterization of certain MSC subpopulations, their precise biological identities and the potential therapeutic advantages over heterogeneous MSCs remains to be fully defined. Here we review the preclinical and clinical advancements in the understanding of the therapeutic properties of MSCs and their subpopulations, assessing the evidence supporting their use in regenerative medicine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.